miRNAs are non-coding RNA molecules; their deregulations may contribute to cancer pathogenesis. However,
the mechanisms of how miRNA dysfunction contributes to the lymphomagenesis of diffuse large B-cell lymphoma
(DLBCL) are not well established. In this study, we analyzed the expression of miR-224 in four DLBCL cell lines and
168 patients’ specimens. We found that the expression of miR-224 in DLBCL was down-regulated compared with normal
B-cell but was not statistically different between the germinal center B-cell-like-type and the activated B-cell-like-type.
Using bioinformatics prediction and luciferase report assays, we demonstrated that miR-224 directly down-regulated
CD59 expression by binding to its 3’-untranslated region. We also used immunohistochemical staining of CD59 in human
DLBCL specimens and analyzed the relationship between the expression of miR-224, CD59 and the overall/progress-free
survival of DLBCL patients who were uniformly treated with rituximab,cyclophosphamide, adriamycin, vincristine, and
prednisone (R-CHOP). We found that miR-224 may contribute to DLBCL pathogenesis. Most importantly, the expression
of miR-224 and CD59 can predict the response and outcome of DLBCL patients treated with R-CHOP.
Keywords: CD59, diffuse large B-cell lymphoma (DLBCL), microRNA (miRNA), miR-224, R-CHOP.
Rights & PermissionsPrintExport